IBSA will once again be back at CphI Worldwide 2022, Frankfurt, 1-3 November, to present its innovative solutions for the pharmaceutical market, developed in cutting-edge R&D centers and realized in state-of-the art technology production sites.
In fact, over the years IBSA’s Researchers have developed innovative technologies, novel formulations and delivery systems such as softgel capsules, orodispersible films, pre-filled syringes, patches (hydrogel and drug-in-adhesive technologies), gonadotripins purification process, progesterone & ßciclodestrine, single dose strip, Nahyco hybrid technology, device for intravesical instillation.
At the CPhI, the group will present some of its latest innovations, such as the IBSA Vitamin D3 pharma, available in two different forms (Orodispersible Films/ODF and softgel) at two different dosages (0.625 and 1.25 mg cholecalciferol, respectively equivalent to 25’000 I.U. and 50’000 I.U.) for a personalized treatment to improve patient compliance. Vitamin D3 is indicated for all those situations where there is the need to prevent vitamin D deficiency, to treat vitamin D deficiency and for the treatment of osteoporosis.
Softgel technology allows a liquid matrix of cholecalciferol, totally dissolved in refinedolive oil, to be incorporated into a soft gelatin capsule, improving the administration of the drug and the patient clearance.
Orodispersible film is an ultrathin strip of postage stamp size that, after placing on the top of the tongue, dissolves within seconds, providing a rapid bioavailability of the drug. No need to chew or swallow, orodispersible films also provide an increased compliance.
Established in Lugano in 1945, IBSA is present in over 90 countries in 5 different continents, with 17 subsidiaries, in Europe, China and the United States and employs more than 2,000 collaborators in its headquarters, subsidiaries and manufacturing sites.
The company has developed an extensive product portfolio that includes different therapeutic categories, such as prescription drugs, OTC medicines, medical devices and food supplements, and covers 10 therapeutic areas.
Thanks to its consolidated experience, its industrial capacity and its proprietary technologies, IBSA is the ideal partner to serve other companies in the pharmaceutical and nutraceutical industry, providing strategic licensing agreements and comprehensive services for EU and non-EU markets.
Come and visit us at CPhI Worldwide 2022, 1-3 November, Stand 90H80, zone ICSE
Visit our website for more information: https://www.businessdevelopment.ibsagroup.com/
